SavedAdd your journal

Journals / Epilepsi / 2015 / Cilt: 21 - Sayı: 2

Rufinamide Use in Refractory Epilepsies

Dirençli Epilepsilerde Rufinamid Kullanımı

Abidin ERDAL
Yasemin AYDEMİR
F. Ezgi TOKUÇ UÇAN
Gizem ÖZDEMİR
GÜLNİHAL KUTLU
Fatma GENÇ
Yasemin GÖMCELİ BİÇER
Journal
Epilepsi
Pages
81–85
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article discusses the efficiency of rufinamide as used in the treatment of five refractor epileptic cases at the Epilepsy Clinic established in Antalya Education and Research Hospital in August 2011.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The drug rufinamide was approved in November 2008 by the US Food and Drug Administration for use in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients older than 4 years.
📊
Key Findings & Data:Lennox-Gastaut Syndrome is one of the most treatment-resistant epilepsies, and seizures require a diversity of polytherapy.
💡
Conclusion & Impact:This article discusses the efficiency of rufinamide as used in the treatment of five refractor epileptic cases at the Epilepsy Clinic established in Antalya Education and Research Hospital in August 2011.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

The drug rufinamide was approved in November 2008 by the US Food and Drug Administration for use in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients older than 4 years. Lennox-Gastaut Syndrome is one of the most treatment-resistant epilepsies, and seizures require a diversity of polytherapy. In recent years, a remarkable number of reports have been published on the effectiveness of rufinamide in childhood epileptic encephalopathy and epileptic spasms, tonic seizures, myoclonic-astatic epilepsy, Dravet syndrome, and refractory partial seizures dependent on migration abnormalities. This article discusses the efficiency of rufinamide as used in the treatment of five refractor epileptic cases at the Epilepsy Clinic established in Antalya Education and Research Hospital in August 2011.

Özet

Rufinamid, dört yaşından büyük hastalarda Lennox-Gastaut Sendromu ile ilişkili nöbetlerin ek tedavisi için Amerikan Gıda ve İlaç Dairesi tarafından Kasım 2008 yılında onaylanan bir ilaçtır. Lennox-Gastaut Sendromu ise tedaviye en dirençli epilepsilerin başında gelmekte, nöbetlerin çeşitliliği politerapiyi zorunlu kılmaktadır. Son yıllarda çocukluk çağı epileptik ensefalopati ve epileptik spazmlar, tonik nöbetler, miyoklonikastatik epilepsi, Dravet sendromu ve migrasyon anormalliklerine bağlı dirençli parsiyel nöbetlerde Rufinamid’in etkinliğini bildiren yayınlar dikkat çekmektedir. Bu yazıda, Ağustos 2011 tarihinde kurulan Antalya Eğitim ve Araştırma Hastanesi Epilepsi Polikliniği’nde Rufinamid’in, dirençli epileptik beş olgudaki etkinliğini değerlendirdik.

🔖

Cite This Article

ERDAL, A., AYDEMİR, Y., UÇAN, F. E. T., ÖZDEMİR, G., KUTLU, G., GENÇ, F., BİÇER, Y. G. (2015). Rufinamide Use in Refractory Epilepsies. Epilepsi, Cilt: 21 - Sayı: 2, 81–85. https://ajindex.com/articles/161393

References (17)

  1. Arroyo S. Rufinamide. Neurotherapeutics 2007;4:155–62
  2. Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr 2013;50:1033–40
  3. Proposal for classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1985;26:268–78
  4. Dervent A. Lennox-Gastaut sendromu. In: Bora İ, Yeni N, Gürses C, editors. Epilepsi. 1st ed. İstanbul: Nobel Tıp Kitabevi; 2008. p. 175–85
  5. Glauser T, Arzimanoglou A, Litzinger M. Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. Epilepsia 2005;46:194–5
  6. Glauser T, Kluger G, Sachdeo R, Krauss G, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950–8
  7. Wheless JW, Conry J, Krauss G, Mann A, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24:1520–5
  8. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf 2011;2:141–58
  9. Coppola G, Zamponi N, Kluger G, Mueller A, et al. Rufinamide for refractory focal seizures: an open-label, multicenter European study. Seizure 2013;22:33–6
  10. Öz B. ubacute sclerosing panencephalitis: Case report and literature review. Cerrahpaşa Tıp Dergisi 2000;31:107–12
  11. Vendrame M, Loddenkemper T, Gooty VD, Takeoka M, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol 2010;43:155–8
  12. Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407
  13. Cusmai R, Verrotti A, Moavero R, Curatolo P, et al. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Res 2014;108:542–6
  14. Coppola G, Grosso S, Franzoni E, Veggiotti P, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol 2011;18:246–51
  15. Hsieh DT, Thiele EA. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013;6:189–98
  16. Albini M, Morano A, Fanella M, Lapenta L, et al. Effectiveness of Rufinamide in the Treatment of Idiopathic Generalized Epilepsy With Atypical Evolution: Case Report and Review of the Literature. Clin EEG Neurosci 2014
  17. Häusler M, Kluger G, Nikanorova M. Epilepsy with myoclonic absences-fav